Explore

Breakthrough in Colorectal Cancer Treatment with Immunotherapy

Breakthrough in Colorectal Cancer Treatment with Immunotherapy

Researchers have announced a significant breakthrough in colorectal cancer treatment, revealing that certain tumors can be eradicated using immunotherapy alone, without the need for chemotherapy or surgery. This development, highlighted by Memorial Sloan Kettering Cancer Center, focuses on colorectal cancers with deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H). Early clinical trials have shown complete tumor remission in some patients, suggesting a potential shift towards less invasive treatment options. This approach could reduce the need for surgeries, which often result in life-altering consequences such as colostomies and long-term bowel dysfunction.

The most hopeful cancer news in years

The most hopeful cancer news in years

Why a roomful of oncologists gave a standing ovation for a line graph.

Melanoma Research Alliance Appoints Stephanie Kauffman as CEO Amidst Research Advancements

Melanoma Research Alliance Appoints Stephanie Kauffman as CEO Amidst Research Advancements

The Melanoma Research Alliance (MRA) has appointed Stephanie Kauffman as its new Chief Executive Officer, effective July 1, 2026. Kauffman succeeds Marc Hurlbert, who will lead the National Kidney Foundation. Under Kauffman's leadership, MRA aims to accelerate melanoma research through strategic collaborations and investments in artificial intelligence, precision medicine, and immunotherapy. The organization has invested over $200 million in research since its inception, contributing to significant therapeutic advancements. Kauffman, previously MRA's President and COO, is poised to lead the organization into a new era of scientific breakthroughs.

New Cancer Treatments Highlighted at ASCO Conference Offer Hope and Challenges

New Cancer Treatments Highlighted at ASCO Conference Offer Hope and Challenges

At the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, researchers presented promising new cancer treatments. Highlights included a smart drug, GRWD5769, which helps immunotherapy drugs expose and attack cancer cells, showing significant tumor reduction in trials. Another breakthrough was a pill, daraxonrasib, doubling survival time for pancreatic cancer patients. Additionally, a genomic test could allow many breast cancer patients to skip chemotherapy. However, challenges remain, such as a failed blood test trial for early cancer detection and a predicted shortage of cancer care workers by 2050 due to rising cancer cases.

'It's still working': More are living with cancer as era of targeted drugs takes hold

'It's still working': More are living with cancer as era of targeted drugs takes hold

By Deena Beasley June 3 (Reuters) - Cathy Smithwick, now 67, has lived with breast cancer, and then ovarian cancer, for more than 20 years with the help of targeted drugs, drugs that harness the body's immune system, chemotherapy and hormone pills.

NICE Approves New Treatment for Chemotherapy-Resistant Ovarian Cancer, Offering Hope to Patients

NICE Approves New Treatment for Chemotherapy-Resistant Ovarian Cancer, Offering Hope to Patients

The National Institute for Health and Care Excellence (NICE) has approved mirvetuximab soravtansine, a targeted therapy for platinum-resistant ovarian cancer, marking the first such approval in over two decades. This treatment is designed for women with certain gynaecological cancers that have stopped responding to standard chemotherapy. It specifically targets folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. The drug binds to cancer cells and delivers the treatment directly, offering a new option for patients who have limited alternatives. Approximately 270 patients are expected to benefit in the first year, with numbers rising as access to testing increases. The treatment is administered via intravenous infusion and is noted for having fewer side effects and requiring fewer hospital visits compared to standard chemotherapy.

Melanoma Research Alliance Appoints Stephanie Kauffman as CEO to Lead New Era in Cancer Research

Melanoma Research Alliance Appoints Stephanie Kauffman as CEO to Lead New Era in Cancer Research

The Melanoma Research Alliance (MRA), a leading nonprofit organization dedicated to funding melanoma research, has announced the appointment of Stephanie Kauffman as its new Chief Executive Officer, effective July 1, 2026. Kauffman will succeed Marc Hurlbert, PhD, who has led the organization for eight years and will transition to the role of CEO at the National Kidney Foundation. Under Hurlbert's leadership, MRA has significantly advanced melanoma research, contributing to the approval of 19 therapeutic approaches. Kauffman, who joined MRA in 2022 as President and Chief Operating Officer, has been instrumental in expanding research investments and partnerships. Her leadership is expected to further accelerate MRA's mission to advance cancer research through innovations in artificial intelligence, precision medicine, and immunotherapy.

Research Highlights Gut Microbiome's Role in Cancer Treatment

Research Highlights Gut Microbiome's Role in Cancer Treatment

Recent research has highlighted the potential role of the gut microbiome in enhancing cancer treatment outcomes. Studies suggest that a healthier gut microbiome may improve the effectiveness of immunotherapy in cancer patients. Researchers are exploring various interventions, including probiotics and dietary changes, to manipulate the gut microbiome and boost immune responses against cancer. This emerging field of study is gaining attention for its potential to revolutionize cancer care by leveraging the body's natural microbiota.

Researchers Identify microRNA-25 as Key to Overcoming Immunotherapy Resistance in Cancer

Researchers Identify microRNA-25 as Key to Overcoming Immunotherapy Resistance in Cancer

Researchers at the University of California San Diego have identified microRNA-25 (miR-25) as a significant factor in the resistance of tumors to immunotherapy. The study, conducted on mouse cancer models, demonstrated that deleting miR-25 sensitizes tumors to immune checkpoint therapy, a form of treatment that helps the immune system recognize and attack cancer cells. The research highlights miR-25's role in creating a treatment-resistant environment by being upregulated in melanoma cell lines and patient samples, contributing to hypoxia-driven immunosuppression. The study utilized CRISPR-Cas9 to knock out the Mir25 gene in various mouse cancer cell lines, which improved the tumors' response to immune checkpoint therapy. This discovery points to the miR-25-SDC3 pathway as a potential target for future therapeutic interventions, aiming to convert 'cold' tumors into more treatment-responsive 'hot' tumors.

'It's still working': More are living with cancer as era of targeted drugs takes hold

'It's still working': More are living with cancer as era of targeted drugs takes hold

By Deena Beasley June 3 (Reuters) - Cathy Smithwick, now 67, has lived with breast cancer, and then ovarian cancer, for more than 20 years with the help of targeted drugs, drugs that harness the body's immune system, chemotherapy and hormone pills.

Legend Biotech's CAR T Therapy Shows 100% Response Rate in Lymphoma Study

Legend Biotech's CAR T Therapy Shows 100% Response Rate in Lymphoma Study

Legend Biotech's CAR T therapy, LB2501, has achieved a 100% response rate in a Phase 1 study of non-Hodgkin lymphoma. All six patients treated with the therapy responded, with five achieving complete remission. The study's results position Legend Biotech as a potential takeover target in the competitive CAR T market. The therapy demonstrated a favorable safety profile, with no dose-limiting toxicities or serious adverse events reported. The trial is ongoing, with further data expected in the coming years.

GLP-1 Drugs Show Potential Benefits in Cancer Treatment

GLP-1 Drugs Show Potential Benefits in Cancer Treatment

Recent studies presented at the American Society of Clinical Oncology meeting suggest that GLP-1 drugs, commonly used for diabetes and weight loss, may offer protective benefits against various cancers. Research involving over 12,000 patients indicates that these drugs are associated with lower risks of cancer progression and improved survival rates, particularly in lung, breast, colorectal, and liver cancers. The studies also suggest that GLP-1 drugs may enhance the effectiveness of immunotherapies. While the exact mechanisms remain unclear, researchers believe the drugs' anti-inflammatory properties and effects on insulin signaling may contribute to these benefits.